Research Publications

Thrombospondin-1 up-regulates expression of cell adhesion molecules and promotes monocyte binding to endothelium.

Narizhneva NV, Razorenova OV, Podrez EA, Chen J, Chandrasekharan UM, DiCorleto PE, Plow EF, Topol EJ, Byzova TV

The relationship between baseline risk and mortality in ST-elevation acute myocardial infarction treated with pharmacological reperfusion: insights from the Global Utilization of Strategies To open Occluded arteries (GUSTO) V trial.

Brener SJ, Lincoff AM, Bates ER, Jia G, Armstrong PW, Guetta V, Hochman JS, Savonitto S, Wilcox RG, White HD, Topol EJ, GUSTO V Investigators

Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial.

Gurm HS, Sarembock IJ, Kereiakes DJ, Young JJ, Harrington RA, Kleiman N, Feit F, Wolski K, Bittl JA, Wilcox R, Topol EJ, Lincoff AM

Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes.

Mahaffey KW, Roe MT, Kilaru R, French JK, Alexander JH, Berdan LG, Van De Werf F, Simoons ML, Weaver WD, White HD, Lincoff AM, Kleiman NS, Topol EJ, Harrington RA

Physicians and the investment industry.

Topol EJ, Blumenthal D

Association of height with outcomes in patients with acute myocardial infarction receiving reperfusion therapy.

Mehta RH, Califf RM, Garg J, Pieper KS, Alexander JH, Moliterno DJ, Van de Werf F, Ohman EM, White HD, Topol EJ, Granger CB

Miscues on the "lack of MEF2A mutations" in coronary artery disease.

Wang Q, Rao S, Topol EJ

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.

Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Baggish JS, Bhatt DL, Topol EJ

Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial.

Hakonarson H, Thorvaldsson S, Helgadottir A, Gudbjartsson D, Zink F, Andresdottir M, Manolescu A, Arnar DO, Andersen K, Sigurdsson A, Thorgeirsson G, Jonsson A, Agnarsson U, Bjornsdottir H, Gottskalksson G, Einarsson A, Gudmundsdottir H, Adalsteinsdottir AE, Gudmundsson K, Kristjansson K, Hardarson T, Kristinsson A, Topol EJ, Gulcher J, Kong A, Gurney M, Thorgeirsson G, Stefansson K

The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.

Berger PB, Best PJ, Topol EJ, White J, DiBattiste PM, Chan AW, Kristensen SD, Herrmann HC, Moliterno DJ